Anne Stidsholt Roug

Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran et autres

To describe the impact of adding a tyrosine kinase inhibitor (TKI) to intensive chemotherapy (IC) on the outcome of de novo BCR::ABL1+ acute myeloid leukemia (AML), we retrospectively analyzed the data of 212 adult AML with ≥20% bone marrow blasts, BCR::ABL1+ or …

fr, se, re, es, co, ca, de, nl, dk, cz, fi (code pays fourni par la source)

Molecular landscape and risk stratification in acute myeloid leukemia – insights from the real-world REFORM-AML cohort

Daniel Tuyet Kristensen, Rasmus Froberg Broendum, Michael Knudsen, Lykke Grubach et autres

ABSTRACT Large genomically annotated acute myeloid leukaemia (AML) datasets exist, but population-based contemporary cohorts remain scarce. Here we report clinicopathological, genomic, and outcome data from Danish AML patients. 2,512 AML patients were identified between 2015-2022, of whom 33.8% had available NGS data …

dk (code pays fourni par la source)

Somatic RUNX1 exonic deletions in myelodysplastic syndrome: A rare yet high‐risk recurrent genetic aberration

Ahmed Al-Djaber, Albin Österroos, Alessandro Baldi, Arielle R. Munters et autres

De två första författarna delar förstaförfattarskapet De två sista författarna delar sistaförfattarskapet

se, de, dk (code pays fourni par la source)

Validity of The Danish National Chronic Myeloid Neoplasia Registry

Dustin Andersen Patel, Karina Kannik, Iman Chanchiri, Peter Brown et autres

Purpose: Myeloproliferative neoplasms (MPN) are rare hematological malignancies with long survival, making real-world evidence essential to complement clinical trial data. The Danish National Chronic Myeloid Neoplasia Registry (DMR) captures nearly all MPN patients nationwide, but its validity has not been systematically evaluated. …

dk (code pays fourni par la source)

One-year cancer risk after detection of blast cells in peripheral blood

Pernille Just Vinholt, Rasmus Bank Lynggaard, Katrine Sølling Borlund Mortensen, Maria Boysen Sandberg et autres

Haematologists are often consulted on the need for additional diagnostic workup in patients with blast cells in peripheral blood. However, cancer risk (including solid tumors) after detection of blast cells in peripheral blood is lacking. Therefore we evaluated the 1-year cancer risk …

One-year cancer risk after detection of blast cells in peripheral blood

Pernille Just Vinholt, Rasmus Bank Lynggaard, Katrine Sølling Borlund Mortensen, Maria Boysen Sandberg et autres

Haematologists are often consulted on the need for additional diagnostic workup in patients with blast cells in peripheral blood. However, cancer risk (including solid tumors) after detection of blast cells in peripheral blood is lacking. Therefore we evaluated the 1-year cancer risk …

One-year cancer risk after detection of blast cells in peripheral blood

Pernille Just Vinholt, Rasmus Bank Lynggaard, Katrine Sølling Borlund Mortensen, Maria Boysen Sandberg et autres

Haematologists are often consulted on the need for additional diagnostic workup in patients with blast cells in peripheral blood. However, cancer risk (including solid tumors) after detection of blast cells in peripheral blood is lacking. Therefore we evaluated the 1-year cancer risk …

dk (code pays fourni par la source)

Exploring the Functional Impact of Individual DDX41 Variants With a Fast and Robust Cell‐Based Method

Nikolaj Juul Nitschke, Marwa Almosailleakh, Issa Ismail Issa, Clara Amanda Skov et autres

Germline DDX41 variants are found in up to 4% of patients with acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDSs), with a higher prevalence among males and a late onset. In this study, we analyzed 647 Danish patients with suspected myeloid neoplasms …

dk (code pays fourni par la source)

Automated risk stratification in myelofibrosis

Daniel Tuyet Kristensen, Tarec Christoffer El‐Galaly, Anne Stidsholt Roug

The landscape of precision oncology increasingly relies on accurate risk stratification tools to guide prognosis and optimize treatment allocation. Myelofibrosis (MF), an aggressive myeloproliferative neoplasm, exemplifies this need. The treatment strategies range widely from a ‘watch-and-wait’ approach or supportive care in lower-risk …

dk (code pays fourni par la source)

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran et autres

Abstract Introduction: De novo BCR::ABL1+ acute myeloid leukemia (AML) is a distinct and rare entity (0.1%-3% of AML), classified as adverse-risk in the ELN 2022 classification (Döhner H et al., Blood 2022). However, we recently published the favorable outcome of 18 de …

fr, se, re, ru, es, co, de, us, nl, dk, cz, fi (code pays fourni par la source)

Real-world risk of vascular events in patients with myeloproliferative neoplasms compared to the danish general population

Dustin Andersen Patel, Volkert Siersma, John Mascarenhas, Kirsten Grønbæk et autres

Abstract Introduction: Treatment in myeloproliferative neoplasms (MPN) aims to lower the risk of thrombotic events, alleviate MPN-related symptoms and prevent disease progression. In Denmark, all patients with MPN are followed at public hospitals that are obligated to report individual-level data to the …

dk, us (code pays fourni par la source)

A Danish nationwide population-based cohort study on acute myeloid leukemia with RUNX1::RUNX1T1 – Real-world outcomes and clinicopathological characteristics

Daniel Tuyet Kristensen, Andreas Due Ørskov, Dennis Lund Hansen, Anni Aggerholm et autres

Core-binding factor (CBF) acute myeloid leukemia (AML) with the RUNX1::RUNX1T1 fusion oncogene resulting from the recurrent balanced translocation t(8;21)(q22;q22.1) was among the first acute leukemias to be defined based on cytogenetics [ 1 ]. It has been estimated to account for 7% …

dk (code pays fourni par la source)